What is the difference between ABATACEPT and SULFASALAZINE?

ABATACEPT is a Other and SULFASALAZINE is a Aminosalicylate (IBD). They reach a similar treatment goal through different pharmacological mechanisms, which is why one may be tolerated by a patient who could not tolerate the other.

Can ABATACEPT and SULFASALAZINE be used for the same conditions?

Both medications are prescribed for overlapping indications including in combination with a calcineurin inhibitor and methotrexate and biologic disease-modifying antirheumatic drugs (bDMARDS). Always verify with your prescriber and the current FDA label before switching.

Is ORENCIA the same as Sulfasalazine?

No. ORENCIA (ABATACEPT) and Sulfasalazine (SULFASALAZINE) are distinct medications. They are sometimes confused because of similar branding or because they treat overlapping conditions, but they have different active ingredients and different safety profiles.

Which has fewer side effects, ABATACEPT or SULFASALAZINE?

Side-effect frequency varies by individual. The side-effect comparison section on this page shows FAERS-reported events for each drug side by side. FAERS is voluntary reporting, so it reflects what patients and clinicians chose to report, not absolute population risk.

Can I switch from ABATACEPT to SULFASALAZINE?

Switching medications should always be done under prescriber supervision. The "patient stories" section on this page includes accounts from people who have made the switch and what their transition felt like, but those are individual experiences, not protocols.

ABATACEPT vs SULFASALAZINE

Compare ABATACEPT (ORENCIA) and SULFASALAZINE (Sulfasalazine) — clinical data, side effects, and patient experiences.

ABATACEPT

ORENCIA · Other

How it works

12.1 Mechanism of Action Abatacept, a selective costimulation modulator, inhibits T-cell (T lymphocyte) activation by binding to CD80 and CD86, thereby blocking interaction with CD...

Approved for

in combination with a calcineurin inhibitor and methotrexate

biologic disease-modifying antirheumatic drugs (bDMARDS)

Janus kinase (JAK) inhibitors] is not recommended. ( 1.5

in combination with a calcineurin inhibitor and methotrexate

Intravenous, SubcutaneousTablet

SULFASALAZINE

Sulfasalazine · Aminosalicylate (IBD)

How it works

Other agent

Approved for

INDICATIONS AND USAGE Sulfasalazine Tablets are indicated: a) in the treatment of mild to moderate ulcerative colitis

and as adjunctive therapy in severe ulcerative colitis

and b) for the prolongation of the remission period between acute attacks of ulcerative colitis.

OralTablet

Quick Comparison

ABATACEPTSULFASALAZINE

Drug Class

Other

Aminosalicylate (IBD)

Route

Intravenous, Subcutaneous

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

ABATACEPT

Drug Not Working

>10%

Joint Pain

1-10%

Fatigue

1-10%

Rash

1-10%

Hair Loss

0.1-1%

SULFASALAZINE

Drug Not Working

>10%

Joint Pain

1-10%

Fatigue

1-10%

Rash

1-10%

Condition Worsened

0.1-1%

Hair Loss

0.1-1%

FDA Warnings

ABATACEPT

5 WARNINGS AND PRECAUTIONS • Concomitant use with a TNF antagonist can increase the risk of infections and serious infections
2) • Serious infections reported
Discontinue if a serious infection develops
1 Increased Risk of Infection with Concomitant Use of TNF Antagonists, Other Biologic RA/PsA Therapy, or JAK Inhibitors In controlled clinical trials in patients with adult RA, patients receiving concomitant intravenous ORENCIA and TNF antagonist therapy experienced more infections (63% vs

SULFASALAZINE

WARNINGS Hepatic, Renal, and Hematologic Toxicity or Other Conditions Only after critical appraisal should Sulfasalazine Tablets be given to patients with hepatic or renal damage or blood dyscrasias
Deaths associated with the administration of sulfasalazine have been reported from hypersensitivity reactions, agranulocytosis, aplastic anemia, other blood dyscrasias, renal and liver damage, irreversible neuromuscular and central nervous system changes, and fibrosing alveolitis
The presence of clinical signs such as sore throat, fever, pallor, purpura, or jaundice may be indications of serious blood disorders or hepatotoxicity
Serious Infections Serious infections, including fatal sepsis and pneumonia, have been reported

Clinical Trial Data

No head-to-head clinical studies found for ABATACEPT vs SULFASALAZINE.

ABATACEPT vs SULFASALAZINE: What You Should Know

Key Differences

ABATACEPT is a Other, while SULFASALAZINE belongs to the Aminosalicylate (IBD) class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles. ABATACEPT is administered via Intravenous or Subcutaneous, whereas SULFASALAZINE uses Oral. Route of administration can affect onset of action and patient adherence.

Safety Considerations

ABATACEPT carries 4 FDA warnings. SULFASALAZINE carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

BALSALAZIDE DISODIUM vs SULFASALAZINE→MESALAMINE vs SULFASALAZINE→ABATACEPT vs ADALIMUMAB→ABATACEPT vs TOCILIZUMAB→ABATACEPT vs LEFLUNOMIDE→ABATACEPT vs METHOTREXATE→

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

ABATACEPT: DailyMed label · FAERS adverse events · ClinicalTrials.gov
SULFASALAZINE: DailyMed label · FAERS adverse events · ClinicalTrials.gov

Loading comparison data...

ABATACEPT vs SULFASALAZINE

Compare ABATACEPT (ORENCIA) and SULFASALAZINE (Sulfasalazine) — clinical data, side effects, and patient experiences.

ABATACEPT

ORENCIA · Other

How it works

12.1 Mechanism of Action Abatacept, a selective costimulation modulator, inhibits T-cell (T lymphocyte) activation by binding to CD80 and CD86, thereby blocking interaction with CD...

Approved for

in combination with a calcineurin inhibitor and methotrexate

biologic disease-modifying antirheumatic drugs (bDMARDS)

Janus kinase (JAK) inhibitors] is not recommended. ( 1.5

in combination with a calcineurin inhibitor and methotrexate

Intravenous, SubcutaneousTablet

SULFASALAZINE

Sulfasalazine · Aminosalicylate (IBD)

How it works

Other agent

Approved for

INDICATIONS AND USAGE Sulfasalazine Tablets are indicated: a) in the treatment of mild to moderate ulcerative colitis

and as adjunctive therapy in severe ulcerative colitis

and b) for the prolongation of the remission period between acute attacks of ulcerative colitis.

OralTablet

Quick Comparison

ABATACEPTSULFASALAZINE

Drug Class

Other

Aminosalicylate (IBD)

Route

Intravenous, Subcutaneous

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

ABATACEPT

Drug Not Working

>10%

Joint Pain

1-10%

Fatigue

1-10%

Rash

1-10%

Hair Loss

0.1-1%

SULFASALAZINE

Drug Not Working

>10%

Joint Pain

1-10%

Fatigue

1-10%

Rash

1-10%

Condition Worsened

0.1-1%

Hair Loss

0.1-1%

FDA Warnings

ABATACEPT

5 WARNINGS AND PRECAUTIONS • Concomitant use with a TNF antagonist can increase the risk of infections and serious infections
2) • Serious infections reported
Discontinue if a serious infection develops
1 Increased Risk of Infection with Concomitant Use of TNF Antagonists, Other Biologic RA/PsA Therapy, or JAK Inhibitors In controlled clinical trials in patients with adult RA, patients receiving concomitant intravenous ORENCIA and TNF antagonist therapy experienced more infections (63% vs

SULFASALAZINE

WARNINGS Hepatic, Renal, and Hematologic Toxicity or Other Conditions Only after critical appraisal should Sulfasalazine Tablets be given to patients with hepatic or renal damage or blood dyscrasias
Deaths associated with the administration of sulfasalazine have been reported from hypersensitivity reactions, agranulocytosis, aplastic anemia, other blood dyscrasias, renal and liver damage, irreversible neuromuscular and central nervous system changes, and fibrosing alveolitis
The presence of clinical signs such as sore throat, fever, pallor, purpura, or jaundice may be indications of serious blood disorders or hepatotoxicity
Serious Infections Serious infections, including fatal sepsis and pneumonia, have been reported

Clinical Trial Data

No head-to-head clinical studies found for ABATACEPT vs SULFASALAZINE.

ABATACEPT vs SULFASALAZINE: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.